KR102117350B1 - 조절 t 세포들의 저해를 위한 방법 및 조성물 - Google Patents

조절 t 세포들의 저해를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR102117350B1
KR102117350B1 KR1020187032175A KR20187032175A KR102117350B1 KR 102117350 B1 KR102117350 B1 KR 102117350B1 KR 1020187032175 A KR1020187032175 A KR 1020187032175A KR 20187032175 A KR20187032175 A KR 20187032175A KR 102117350 B1 KR102117350 B1 KR 102117350B1
Authority
KR
South Korea
Prior art keywords
cells
emth
treg
cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187032175A
Other languages
English (en)
Korean (ko)
Other versions
KR20180123183A (ko
Inventor
마이클 하-노이
Original Assignee
이뮤노베이티브 테라피스, 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노베이티브 테라피스, 엘티디. filed Critical 이뮤노베이티브 테라피스, 엘티디.
Publication of KR20180123183A publication Critical patent/KR20180123183A/ko
Application granted granted Critical
Publication of KR102117350B1 publication Critical patent/KR102117350B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4262—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020187032175A 2010-04-13 2011-04-12 조절 t 세포들의 저해를 위한 방법 및 조성물 Active KR102117350B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32355710P 2010-04-13 2010-04-13
US61/323,557 2010-04-13
PCT/US2011/032090 WO2011130249A2 (en) 2010-04-13 2011-04-12 Methods and compositions for inhibition of treg cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127028850A Division KR20130060188A (ko) 2010-04-13 2011-04-12 조절 t 세포들의 저해를 위한 방법 및 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014991A Division KR20200063262A (ko) 2010-04-13 2011-04-12 조절 t 세포들의 저해를 위한 방법 및 조성물

Publications (2)

Publication Number Publication Date
KR20180123183A KR20180123183A (ko) 2018-11-14
KR102117350B1 true KR102117350B1 (ko) 2020-06-02

Family

ID=44761077

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187032175A Active KR102117350B1 (ko) 2010-04-13 2011-04-12 조절 t 세포들의 저해를 위한 방법 및 조성물
KR1020127028850A Ceased KR20130060188A (ko) 2010-04-13 2011-04-12 조절 t 세포들의 저해를 위한 방법 및 조성물
KR1020207014991A Ceased KR20200063262A (ko) 2010-04-13 2011-04-12 조절 t 세포들의 저해를 위한 방법 및 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020127028850A Ceased KR20130060188A (ko) 2010-04-13 2011-04-12 조절 t 세포들의 저해를 위한 방법 및 조성물
KR1020207014991A Ceased KR20200063262A (ko) 2010-04-13 2011-04-12 조절 t 세포들의 저해를 위한 방법 및 조성물

Country Status (12)

Country Link
US (2) US20110250173A1 (enExample)
EP (1) EP2558123B1 (enExample)
JP (2) JP6294666B2 (enExample)
KR (3) KR102117350B1 (enExample)
CN (1) CN103002915B (enExample)
AU (3) AU2011240752B2 (enExample)
BR (1) BR112012026007A2 (enExample)
CA (1) CA2796053A1 (enExample)
IL (2) IL275017B2 (enExample)
PH (1) PH12012502233A1 (enExample)
SG (2) SG184819A1 (enExample)
WO (1) WO2011130249A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102117350B1 (ko) * 2010-04-13 2020-06-02 이뮤노베이티브 테라피스, 엘티디. 조절 t 세포들의 저해를 위한 방법 및 조성물
EP3091990B1 (en) 2014-01-08 2021-05-12 Mirror Biologics, Inc. Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
TWI714529B (zh) * 2015-05-20 2021-01-01 以色列商梵提夫免疫療法公司 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療
EP3400074B1 (en) * 2016-01-07 2021-10-20 B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University Compositions for generating immunotolerant responses
CN110177558B (zh) * 2016-09-16 2025-02-28 贝勒医学院 用于病毒特异性t细胞的活化和扩增的平台
KR102507852B1 (ko) * 2020-01-10 2023-03-09 이뮤노바이옴 주식회사 신규한 락토바실러스 플란타룸(Lactobacillus plantarum) 균주, 균주 유래 다당체 및 이의 용도
GB202007321D0 (en) * 2020-05-18 2020-07-01 Inst De Medicina Molecular Joaeo Lobo Antunes T cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009135199A2 (en) * 2008-05-02 2009-11-05 Immunovative Therapies, Ltd. Vaccine compositions and methods

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US6797480B1 (en) 1998-10-05 2004-09-28 University Of Connecticut Health Center Purification of heat shock/stress protein cell surface receptors and their use as immunotherapeutic agents
EE200100203A (et) * 1998-10-05 2002-10-15 M & E Biotech A/S Meetod immuunvastuse indutseerimiseks polüpeptiidse antigeeni vastu ja rakuga seotud polüpeptiidse antigeeni mahasurumiseks loomorganismil, selle meetodi kasutamine eesnäärme- ja rinnavähi raviks ning immunogeenne kompositsioon
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6875849B2 (en) 2001-05-01 2005-04-05 Arizona Board Of Regents Of Behalf Of The University Of Arizona Methods of recovering chaperone proteins and complexes thereof
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
JPWO2003028758A1 (ja) * 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US20080267964A1 (en) * 2005-02-17 2008-10-30 Masaki Terabe Synergistic Effect of Tgf-Beta Blockade and Immunogenic Agents on Tumors
KR20080090413A (ko) * 2005-12-08 2008-10-08 유니버시티 오브 루이빌 리서치 파운데이션, 인코포레이티드 Ｔ 조절 세포의 확장을 위한 방법 및 조성물
JP5254952B2 (ja) * 2006-04-13 2013-08-07 イミュノバティブ セラピーズ， リミテッド 日和見感染症の治療のための同種異系細胞治療
US20080112963A1 (en) * 2006-11-13 2008-05-15 Immunovative Therapies, Ltd. Ablative immunotherapy
US7972594B2 (en) * 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
WO2008126940A1 (ja) * 2007-04-10 2008-10-23 The University Of Tokyo 新規ｔ細胞
US9695397B2 (en) * 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
EP2141245A1 (en) * 2008-07-03 2010-01-06 Ivana Türbachova DNA methylation analysis of regulatory T cells through DNA-methylation analysis of the TSDR region of the gene foxP3
KR102117350B1 (ko) * 2010-04-13 2020-06-02 이뮤노베이티브 테라피스, 엘티디. 조절 t 세포들의 저해를 위한 방법 및 조성물
US10479975B2 (en) * 2014-06-06 2019-11-19 Bluebird Bio, Inc. Methods of making T cell compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009135199A2 (en) * 2008-05-02 2009-11-05 Immunovative Therapies, Ltd. Vaccine compositions and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Immunotoxicology, 2009.11.16.(온라인 공개), 제7권, 제1호, 페이지 15-26*
Leukemia Research, 2009, 제33권, 제4호, 페이지 525-538

Also Published As

Publication number Publication date
CN103002915B (zh) 2015-09-23
JP2016155851A (ja) 2016-09-01
KR20130060188A (ko) 2013-06-07
US20160361404A1 (en) 2016-12-15
EP2558123A2 (en) 2013-02-20
JP2013523886A (ja) 2013-06-17
AU2018204834A1 (en) 2018-08-02
IL275017B1 (en) 2024-03-01
PH12012502233A1 (en) 2022-10-05
IL275017A (en) 2020-07-30
KR20200063262A (ko) 2020-06-04
BR112012026007A2 (pt) 2016-06-28
AU2016231642B2 (en) 2018-04-05
AU2018204834B2 (en) 2020-02-06
WO2011130249A3 (en) 2012-03-08
EP2558123B1 (en) 2023-08-09
SG10201509539UA (en) 2015-12-30
KR20180123183A (ko) 2018-11-14
CA2796053A1 (en) 2011-10-20
AU2011240752B2 (en) 2016-07-28
AU2011240752A1 (en) 2012-11-08
US20110250173A1 (en) 2011-10-13
IL222343A0 (en) 2012-12-31
IL222343B (en) 2020-06-30
WO2011130249A2 (en) 2011-10-20
IL275017B2 (en) 2024-07-01
JP6294666B2 (ja) 2018-03-14
CN103002915A (zh) 2013-03-27
SG184819A1 (en) 2012-11-29
AU2016231642A1 (en) 2016-10-27
HK1184362A1 (en) 2014-01-24
EP2558123A4 (en) 2014-03-19
EP2558123C0 (en) 2023-08-09

Similar Documents

Publication Publication Date Title
AU2018204834B2 (en) METHODS AND COMPOSITIONS FOR INHIBITION OF Treg CELLS
US12220451B2 (en) Cell-based vaccine compositions and methods of use
Oth et al. Pathogen‐associated molecular patterns induced crosstalk between dendritic cells, T helper cells, and natural killer helper cells can improve dendritic cell vaccination
KR20110002496A (ko) 백신 조성물 및 방법
Poehlein et al. Depletion of tumor‐induced Treg prior to reconstitution rescues enhanced priming of tumor‐specific, therapeutic effector T cells in lymphopenic hosts
Janikashvili et al. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia
Keshavarz-Fathi et al. Cancer Immunology
US20170274069A1 (en) Method for the cancer treatment and prevention of metastatic disease
Thomas et al. Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell–engrafted NOD/SCID/IL-2Rγcnull mice
Roy et al. Type 1 interferon mediated signaling is indispensable for eliciting anti-tumor responses by Mycobacterium indicus pranii
HK1184362B (en) Methods and compositions for inhibition of treg cells
ES2673321T3 (es) Método para la maduración in vitro de células dendríticas
Li Adoptive Cell Therapy using CD4 T Helper 1-like and CD8 Cytotoxic T Lymphocytes in a Mouse Model of Melanoma
Salem et al. Higher Activities of Hepatic Versus Splenic CD8+ T Cells in Responses to Adoptive T Cell Therapy and Vaccination of B6 Mice with MHC Class-1 Binding Antigen
Lerret DNA vaccination combined with low-dose total body irradiation induces long-term breast tumor regression
Zhang Tolerogenic CD4⁻ 8⁻ Dendritic Cells and their Conversion into Immunogenic Ones via TLR9 Signaling
Goding Induction of anti-tumor responses via adoptively transferred, cytokine-gene transduced A-NK cells
Jensen adenocarcinoma, 4T1
Kuhn Using natural adjuvants to stimulate anti-tumour immune responses
Church The role of CD4 [superscript+] T cells during adoptive and active-specific cancer immunotherapy
Yewdall In vivo mechanisms of naive CD8+ T cell activation by dendritic cell vaccines
Wennerberg Natural killer cells in cancer: studies on migration and cytotoxicity

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181106

Application number text: 1020127028850

Filing date: 20121102

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181128

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190105

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191127

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190105

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20191127

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190628

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20200311

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20200219

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20191127

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20190628

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200526

Application number text: 1020127028850

Filing date: 20121102

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200526

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200527

End annual number: 3

Start annual number: 1

PG1601 Publication of registration